Sally Beauty Holdings Inc. (NYSE:SBH) represented a move of -0.23 percent or $-0.1 per share and closed its previous day trading session at $17.39. 1.21 Million Shares were traded in the last trading session with an Average Volume of 2.14 Million Shares. The stock currently has a Market Capitalization of 2.22 Billion.
Sally Beauty Holdings, Inc. is an international specialty retailer and distributor of professional beauty products supplier. Through the Sally Beauty Supply and Beauty Systems Group businesses, the Company sells and distributes through world. Sally Beauty Supply stores offer up to 9,000 products for hair, skin, and nails through professional lines such as OPI, China Glaze, Wella, Clairol, Conair and Hot Shot Tools, as well as an extensive selection of proprietary merchandise. Beauty Systems Group stores, branded as CosmoProf or Armstrong McCall stores, along with its outside sales consultants, sell up to 10,000 professionally branded products including Paul Mitchell, Wella, Matrix, Schwarzkopf, Kenra, Goldwell, Joico and Aquage, intended for use in salons and for resale by salons to retail consumers.
The stock traded between $14.05 and $21.36 over 1-Year time period showing its price to sales ratio of 0.56. Sally Beauty Holdings Inc. (NYSE:SBH) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-0.43 and 200-Day Simple Moving Average of $-4.87. Its Price to Free Cash Flow is 8.11 and Price to Book of 0.
Analyst’s recommended the stock as 2.9 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Sally Beauty Holdings Inc. (NYSE:SBH) reported its Actual EPS of $0.68/share. The analysts offering Earnings Estimates for the company were believing that Sally Beauty Holdings Inc. could bring EPS of $0.42/share. The difference between Actual EPS and Estimated EPS was 0.26 Percent. Thus showing an Earnings Surprise of 61.9 Percent.
NovoCure Limited (NASDAQ:NVCR)
In the last trading session, NovoCure Limited (NASDAQ:NVCR) added its value by 3.2% closing at the price of $22.55. The stock currently has market capitalization of 1.89 Billion, with average volume of 860.02 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently NovoCure Limited (NASDAQ:NVCR) is showing beta of 0. This particular value of beta suggests that NovoCure Limited (NASDAQ:NVCR) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for NovoCure Limited (NASDAQ:NVCR) is at $-1.09.
The stock currently has RSI of 59.38. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.
NovoCure Limited (NASDAQ:NVCR) topped its 52-week high price of $24.15 on 01/29/18 and 52-Week Low Price of $ 6.75 on 03/27/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.28% and monthly volatility of 5.10% respectively.